{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:41:16Z","timestamp":1789764076808,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1038\/s41434-024-00456-y","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T11:02:56Z","timestamp":1717585376000},"page":"391-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Gene replacement therapy for spinal muscular atrophy: safety and preliminary efficacy in a Brazilian cohort"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7520-3353","authenticated-orcid":false,"given":"Rodrigo Holanda","family":"Mendon\u00e7a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Banzzatto","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Matsui Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Kerstenetzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Fernando","family":"Grossklauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Silveira-Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziela Jorge","family":"Polido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmar","family":"Zanoteli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"456_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1136\/adc.45.239.33","volume":"45","author":"DF Roberts","year":"1970","unstructured":"Roberts DF, Chavez J, Court SD. The genetic component in child mortality. Arch Dis Child. 1970;45:33\u20138.","journal-title":"Arch Dis Child"},{"key":"456_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155\u201365.","journal-title":"Cell"},{"key":"456_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20:27\u201332.","journal-title":"Eur J Hum Genet"},{"key":"456_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","volume":"2","author":"TL Munsat","year":"1992","unstructured":"Munsat TL, Davies KE. International SMA consortium meeting (26-28 June 1992, Bonn, Germany). Neuromuscul Disord. 1992;2:423\u20138.","journal-title":"Neuromuscul Disord"},{"key":"456_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 2014;83:810\u20137.","journal-title":"Neurology"},{"key":"456_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82:883\u201391.","journal-title":"Ann Neurol"},{"key":"456_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ng854","volume":"30","author":"L Cartegni","year":"2002","unstructured":"Cartegni L, Krainer AR. Disruption of an SF2\/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet. 2002;30:377\u201384.","journal-title":"Nat Genet"},{"key":"456_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","volume":"119","author":"B Wirth","year":"2006","unstructured":"Wirth B, Brichta L, Schrank B, Lochm\u00fcller H, Blick S, Baasner A, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006;119:422\u20138.","journal-title":"Hum Genet"},{"key":"456_CR9","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"key":"456_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625\u201335.","journal-title":"N Engl J Med"},{"key":"456_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915\u201323.","journal-title":"N Engl J Med"},{"key":"456_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1590\/0004-282X-ANP-2022-S135","volume":"80","author":"RH Mendon\u00e7a","year":"2022","unstructured":"Mendon\u00e7a RH, Zanoteli E. Gene therapy in neuromuscular disorders. Arq Neuropsiquiatr. 2022;80:249\u201356. https:\/\/doi.org\/10.1590\/0004-282X-ANP-2022-S135.","journal-title":"Arq Neuropsiquiatr"},{"key":"456_CR13","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med"},{"key":"456_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:284\u201393.","journal-title":"Lancet Neurol"},{"key":"456_CR15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al.Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832\u201341.","journal-title":"Lancet Neurol"},{"key":"456_CR16","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med. 2022;28:1381\u20139.","journal-title":"Nat Med"},{"key":"456_CR17","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med. 2022;28:1390\u20137.","journal-title":"Nat Med"},{"key":"456_CR18","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs. 2019;79:1255\u201362.","journal-title":"Drugs"},{"key":"456_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","volume":"225","author":"AG Feldman","year":"2020","unstructured":"Feldman AG, Parsons JA, Dutmer CM, Veerapandiyan A, Hafberg E, Maloney N, et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020;225:252\u20138.e1.","journal-title":"J Pediatr"},{"key":"456_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","volume":"231","author":"DH Chand","year":"2020","unstructured":"Chand DH, Zaidman C, Arya K, Millner R, Farrar MA, Mackie FE, et al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2020;231:265\u20138.","journal-title":"J Pediatr"},{"key":"456_CR21","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand D, Mohr F, McMillan H, Tukov FF, Montgomery K, Kleyn A, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74:560\u201366.","journal-title":"J Hepatol"},{"key":"456_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/mus.27363","volume":"64","author":"EA Kichula","year":"2021","unstructured":"Kichula EA, Proud CM, Farrar MA, Kwon JM, Saito K, Desguerre I, et al. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy. Muscle Nerve. 2021;64:413\u201327.","journal-title":"Muscle Nerve"},{"key":"456_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01356-1","volume":"15","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Lucibello S, Perulli M, Coratti G, de Sanctis R, Pera MC, et al. Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis. 2020;15:84.","journal-title":"Orphanet J Rare Dis"},{"key":"456_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02379.x","volume":"450","author":"WHO Multicentre Growth Reference Study Group.","year":"2006","unstructured":"WHO Multicentre Growth Reference Study Group. WHO motor development study: windows of achievement for six gross motor development milestones. Acta Paediatr. 2006;450:86\u201395.","journal-title":"Acta Paediatr"},{"key":"456_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","volume":"6","author":"C Wei\u00df","year":"2022","unstructured":"Wei\u00df C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022;6:17\u201327.","journal-title":"Lancet Child Adolesc Health"},{"key":"456_CR26","doi-asserted-by":"crossref","unstructured":"Bitetti I, Lanzara V, Margiotta G, Varone A. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. Gene Ther. 2023;30:592\u2013597.","DOI":"10.1038\/s41434-022-00341-6"},{"key":"456_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JND-200533","volume":"8","author":"R de Holanda Mendon\u00e7a","year":"2021","unstructured":"de Holanda Mendon\u00e7a R, Jorge Polido G, Ciro M, Jorge Fontoura Solla D, Conti Reed U, Zanoteli E. Clinical outcomes in patients with spinal muscular atrophy type 1 treated with nusinersen. J Neuromuscul Dis. 2021;8:217\u201324.","journal-title":"J Neuromuscul Dis"},{"key":"456_CR28","doi-asserted-by":"crossref","unstructured":"Pechmann A, Behrens M, D\u00f6rnbrack K, Tassoni A, Stein S, Vogt S, et al. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain. 2023;146:668\u2013677.","DOI":"10.1093\/brain\/awac252"},{"key":"456_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/dmcn.15171","volume":"64","author":"H Weststrate","year":"2022","unstructured":"Weststrate H, Stimpson G, Thomas L, Scoto M, Johnson E, Stewart A, et al. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen. Dev Med Child Neurol. 2022;64:907\u201314.","journal-title":"Dev Med Child Neurol"},{"key":"456_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/acn3.51519","volume":"9","author":"AM D\u2019Silva","year":"2022","unstructured":"D\u2019Silva AM, Holland S, Kariyawasam D, Herbert K, Barclay P, Cairns A, et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann Clin Transl Neurol. 2022;9:339\u201350. https:\/\/doi.org\/10.1002\/acn3.51519.","journal-title":"Ann Clin Transl Neurol"},{"key":"456_CR31","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.3390\/jcm10235540","volume":"10","author":"A Mirea","year":"2021","unstructured":"Mirea A, Shelby ES, Axente M, Badina M, Padure L, Leanca M, et al. Combination therapy with nusinersen and onasemnogene abeparvovec-xioi in spinal muscular atrophy type I. J Clin Med. 2021;10:5540.","journal-title":"J Clin Med"},{"key":"456_CR32","doi-asserted-by":"publisher","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","volume":"146","author":"MA Waldrop","year":"2020","unstructured":"Waldrop MA, Karingada C, Storey MA, Powers B, Iammarino MA, Miller NF, et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics 2020;146:e20200729. https:\/\/doi.org\/10.1542\/peds.2020-0729.","journal-title":"Pediatrics"},{"key":"456_CR33","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78:834\u201341.","journal-title":"JAMA Neurol"},{"key":"456_CR34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","volume":"33","author":"A Philippidis","year":"2022","unstructured":"Philippidis A. Novartis confirms deaths of two patients treated with gene therapy zolgensma. Hum Gene Ther. 2022;33:842\u20134.","journal-title":"Hum Gene Ther"},{"key":"456_CR35","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.bbmt.2016.02.020","volume":"22","author":"Y Matsumura-Kimoto","year":"2016","unstructured":"Matsumura-Kimoto Y, Inamoto Y, Tajima K, Kawajiri A, Tanaka T, Hirakawa T, et al. Association of cumulative steroid dose with risk of infection after treatment for severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:1102\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"456_CR36","doi-asserted-by":"publisher","first-page":"e20161209","DOI":"10.1542\/peds.2016-1209","volume":"138","author":"HD Davies","year":"2016","unstructured":"Davies HD, Committee on Infectious Diseases. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics 2016;138:e20161209.","journal-title":"Pediatrics"},{"key":"456_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pediatrneurol.2022.05.001","volume":"132","author":"DH Chand","year":"2022","unstructured":"Chand DH, Mitchell S, Sun R, LaMarca N, Reyna SP, Sutter T. Safety of onasemnogene abeparvovec for patients with spinal muscular atrophy 8.5 kg or heavier in a global managed access program. Pediatr Neurol. 2022;132:27\u201332.","journal-title":"Pediatr Neurol"},{"key":"456_CR38","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1212\/WNL.0000000000200676","volume":"98","author":"K Yazaki","year":"2022","unstructured":"Yazaki K, Sakuma S, Hikita N, Fujimaru R, Hamazaki T. Child neurology: pathologically confirmed thrombotic microangiopathy caused by onasemnogene abeparvovec treatment for SMA. Neurology 2022;98:808\u201313.","journal-title":"Neurology"},{"key":"456_CR39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1055\/a-1538-4936","volume":"234","author":"D Witte","year":"2022","unstructured":"Witte D, Hartmann H, Drube J, Haffner D, Illsinger S. [Thrombotic microangiopathy (TMA) after gene replacemant therapy (GRT) due to spinal muscular atrophy: case summary and recommendations for treatment]. Klin Padiatr. 2022;234:42\u201347.","journal-title":"Klin Padiatr"},{"key":"456_CR40","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","volume":"6","author":"J Guillou","year":"2022","unstructured":"Guillou J, de Pellegars A, Porcheret F, Fr\u00e9meaux-Bacchi V, Allain-Launay E, Debord C, et al. Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv. 2022;6:4266\u201370.","journal-title":"Blood Adv"},{"key":"456_CR41","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.3233\/JND-210678","volume":"8","author":"N Elangkovan","year":"2021","unstructured":"Elangkovan N, Dickson G. Gene therapy for duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8:S303\u201316. https:\/\/doi.org\/10.3233\/JND-210678.","journal-title":"J Neuromuscul Dis"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00456-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00456-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00456-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T09:14:27Z","timestamp":1721294067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00456-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":41,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1038\/s41434-024-00456-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2527927\/v1","asserted-by":"object"}]},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RHM received fee from Novartis for speaking at symposia and participating in clinical trials. ABO received fee from Novartis for speaking at symposiums. EZ received fee from Novartis for speaking at symposia and participating in clinical trials. Other authors declare no conflicts of interest in relation to this publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics and Research Committee of the Faculdade de Medicine da Universidade de S\u00e3o Paulo (FMUSP), under reference number 87773118.7.0000.0068. An informed consent was obtained from all subjects for retrospective data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}